Dr Alma Fulurija is an Australian graduate from Perth, attracted back from Switzerland after a successful career in the fields of novel vaccines and immunology.
She has a wide variety of experience in vaccine development and immunotherapy including at Cytos Biotechnology which was voted Switzerland’s most exciting new biotechnology startup float in 2005. She has also worked at the WHO Centre for Neonatal Immunology and Vaccinology in Geneva and has collaborated with Novartis and Pfizer on a number of projects.
Dr Fulurija’s key expertise lies in in vivo pre-clinical models, as well as clinical and regulatory requirements for Phase I/II clinical trials. She was Ondek’s Head of immunology and translational research and Head of research & development during an almost 12-year tenure. She is also an adjunct associate professor at the University of Western Australia.
